INDIVIOR PHARMACEUTICALS INC (INDV) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:INDV • US45579U1097

34.47 USD
+0.02 (+0.06%)
Last: Feb 6, 2026, 11:53 AM
Fundamental Rating

5

Taking everything into account, INDV scores 5 out of 10 in our fundamental rating. INDV was compared to 191 industry peers in the Pharmaceuticals industry. While INDV belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. INDV is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year INDV was profitable.
  • In the past year INDV had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: INDV reported negative operating cash flow in multiple years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • INDV has a better Return On Assets (8.62%) than 90.05% of its industry peers.
  • The Return On Invested Capital of INDV (50.62%) is better than 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for INDV is significantly above the industry average of 12.87%.
  • The last Return On Invested Capital (50.62%) for INDV is above the 3 year average (43.06%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • With an excellent Profit Margin value of 10.34%, INDV belongs to the best of the industry, outperforming 83.77% of the companies in the same industry.
  • INDV's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 24.49%, INDV belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
  • In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
  • INDV has a better Gross Margin (85.51%) than 88.48% of its industry peers.
  • INDV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INDV is creating value.
  • The number of shares outstanding for INDV has been reduced compared to 1 year ago.
  • INDV has less shares outstanding than it did 5 years ago.
  • INDV has a worse debt/assets ratio than last year.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • INDV has an Altman-Z score of 2.72. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.72, INDV is doing good in the industry, outperforming 65.44% of the companies in the same industry.
  • INDV has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as INDV would need 2.68 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.68, INDV belongs to the best of the industry, outperforming 92.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.72
ROIC/WACC5.44
WACC9.3%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.96, INDV is not doing good in the industry: 86.39% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.79 indicates that INDV may have some problems paying its short term obligations.
  • INDV's Quick ratio of 0.79 is on the low side compared to the rest of the industry. INDV is outperformed by 82.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 256.36%, which is quite impressive.
  • Measured over the past years, INDV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -53.19% on average per year.
  • The Revenue has decreased by -0.25% in the past year.
  • INDV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.64% yearly.
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%

3.2 Future

  • Based on estimates for the next years, INDV will show a very strong growth in Earnings Per Share. The EPS will grow by 37.61% on average per year.
  • The Revenue is expected to grow by 1.36% on average over the next years.
EPS Next Y440.8%
EPS Next 2Y159.09%
EPS Next 3Y96.27%
EPS Next 5Y37.61%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.59, the valuation of INDV can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 84.29% of the companies listed in the same industry.
  • INDV's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.67.
  • A Price/Forward Earnings ratio of 11.67 indicates a reasonable valuation of INDV.
  • INDV's Price/Forward Earnings ratio is rather cheap when compared to the industry. INDV is cheaper than 85.86% of the companies in the same industry.
  • INDV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.20.
Industry RankSector Rank
PE 17.59
Fwd PE 11.67
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 84.29% of the companies listed in the same industry.
  • 80.10% of the companies in the same industry are more expensive than INDV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 35.86
EV/EBITDA 13.26
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • INDV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of INDV may justify a higher PE ratio.
  • INDV's earnings are expected to grow with 96.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y159.09%
EPS Next 3Y96.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (2/6/2026, 11:53:45 AM)

34.47

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30
Earnings (Next)02-18
Inst Owners92.33%
Inst Owner Change0.61%
Ins Owners3.78%
Ins Owner Change5.64%
Market Cap4.30B
Revenue(TTM)1.18B
Net Income(TTM)122.00M
Analysts84.62
Price Target43.71 (26.81%)
Short Float %9.74%
Short Ratio4.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.21%
PT rev (3m)193.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.43%
EPS NY rev (3m)81.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1%
Revenue NY rev (3m)13.87%
Valuation
Industry RankSector Rank
PE 17.59
Fwd PE 11.67
P/S 3.65
P/FCF 35.86
P/OCF 23.91
P/B N/A
P/tB N/A
EV/EBITDA 13.26
EPS(TTM)1.96
EY5.69%
EPS(NY)2.95
Fwd EY8.57%
FCF(TTM)0.96
FCFY2.79%
OCF(TTM)1.44
OCFY4.18%
SpS9.45
BVpS-1.66
TBVpS-1.67
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.72
F-Score8
WACC9.3%
ROIC/WACC5.44
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
EPS Next Y440.8%
EPS Next 2Y159.09%
EPS Next 3Y96.27%
EPS Next 5Y37.61%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1050.98%
EBIT Next 3Y148.27%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


What is the profitability of INDV stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


How financially healthy is INDIVIOR PHARMACEUTICALS INC?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?

The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.